Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolrestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 known ✓ | P15121 | 1/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 1.00 |
| ▸ | AKR1A1 | P14550 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | STAT6 | P42226 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 2/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GYS1 | P13807 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolrestat SCHEMBL20769758 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1A1AKR1B1CYP2C9ALDH1A1 | |
| Tolrestat SCHEMBL49326 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1A1AKR1B1CYP2C9ALDH1A1 | |
| Tolrestat SCHEMBL10391297 | 0.99 | AKR1B10 (0.98) | AKR1B10AKR1A1AKR1B1CYP2C9ALDH1A1 | |
| SCHEMBL10527714 | 0.91 | AKR1B10 (0.84) | AKR1B10AKR1A1AKR1B1CYP2C9ALDH1A1 | |
| Tolrestat SCHEMBL10391296 | 0.90 | AKR1B10 (0.82) | AKR1B10AKR1A1AKR1B1CYP2C9ALDH1A1 | |
| SCHEMBL9761952 | 0.90 | AKR1B10 (0.82) | AKR1B10AKR1A1AKR1B1CYP2C9ALDH1A1 | |
| SCHEMBL10352891 | 0.90 | AKR1B10 (0.82) | AKR1B10AKR1A1AKR1B1CYP2C9ALDH1A1 | |
| SCHEMBL10527796 | 0.89 | AKR1B10 (0.81) | AKR1B10AKR1A1AKR1B1CYP2C9ALDH1A1 | |
| SCHEMBL10352914 | 0.89 | AKR1B10 (0.80) | AKR1B10AKR1A1AKR1B1CYP2C9ALDH1A1 | |
| SCHEMBL10352852 | 0.88 | AKR1B10 (0.79) | AKR1B10AKR1A1AKR1B1CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177348-A1 | Methods for Fructokinase Meditation of Alcohol Craving and Alcohol Induced Liver Disease | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-06-05 | — | — | US | claimed |
| US-11293015-B2 | Diels-Alderase and use thereof | PEKING UNIVERSITY (CN) | 2022-04-05 | — | — | US | claimed |
| US-12617854-B2 | Humanized or chimeric CD3 antibodies | GENMAB A/S (DK) | 2026-05-05 | — | — | US | disclosed |
| EP-3634453-B1 | PLANT EXTRACTS WITH ANTI-DIABETIC AND OTHER USEFUL ACTIVITIES | HOUSEY PHARMACEUTICAL RES LABORATORIES L L C (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3484922-B1 | MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137 | GENMAB AS (DK) | 2026-04-29 | — | — | EP | disclosed |
| US-12611380-B2 | Solution and method for reducing the virulence of viruses, bacteria, yeasts, or fungus | Changaris, David (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4678661-A2 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 | Genmab A/S (DK) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025260115-A1 | ANTIFUNGAL COMPOUNDS AND METHODS FOR MAKING THE SAME | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2025-12-26 | — | — | WO | disclosed |
| US-20250368695-A1 | Atranorin biosynthesis gene derived from lichens and uses thereof | INDUSTRY ACADEMIC COOPERATION FOUNDATION OF SUNCHON NATIONAL UNIV (KR) | 2025-12-04 | — | — | US | disclosed |
| WO-2025235845-A1 | ANTIBIOTIC COMPOSITIONS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12454550-B2 | Compositions and methods for bioorthogonal surface coating | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-10-28 | — | — | US | disclosed |
| CN-114478792-A | Bispecific antibodies against CD3 and CD20 | 根马布股份公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114425077-A | SIRP polypeptide compositions and methods of use | 起源生物医药公司 | 2022-05-03 | — | — | CN | disclosed |
| US-11293015-B2 | Diels-Alderase and use thereof | PEKING UNIVERSITY (CN) | 2022-04-05 | — | — | US | disclosed |
| US-11293015-B2 | Diels-Alderase and use thereof | PEKING UNIVERSITY (CN) | 2022-04-05 | — | — | US | disclosed |
| US-11293015-B2 | Diels-Alderase and use thereof | PEKING UNIVERSITY (CN) | 2022-04-05 | — | — | US | disclosed |
| CN-109729716-B | PI3K inhibitor combination | 拜耳制药股份公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20220071902-A1 | SOLUTION AND METHOD FOR REDUCING THE VIRULENCE OF VIRUSES, BACTERIA, YEASTS, OR FUNGUS | Changaris, David G (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220064317-A1 | MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137 | BioNTech SE (DE) | 2022-03-03 | — | — | US | disclosed |
| US-20220033510-A1 | MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137 | BioNTech SE (DE) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617854-B2 | Humanized or chimeric CD3 antibodies | IGLV6-57, IGSF11, FCGRT | AKR1B1 3065/4885AKR1B10 4090/4885AKR1A1 3032/4885 |
| US-12611380-B2 | Solution and method for reducing the virulence of viruses, bacteria, yeasts, or fungus | SARS1, ARG1, PADI1 | AKR1B1 1626/4885AKR1B10 2121/4885AKR1A1 1057/4885 |
| US-20250177348-A1 | Methods for Fructokinase Meditation of Alcohol Craving and Alcohol Induced Liver Disease | KHK, GCK, FN3K | AKR1B1 277/4885AKR1B10 392/4885AKR1A1 398/4885 |
| US-12454550-B2 | Compositions and methods for bioorthogonal surface coating | TYR, TH, TDO2 | AKR1B1 364/4885AKR1B10 340/4885AKR1A1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.